+ Click for EPISODE TRANSCRIPT
DISCLAIMER:
This text is the output of AI based transcribing from an audio recording. Although the transcription is largely accurate, in some cases it is incomplete or inaccurate due to inaudible passages or transcription errors and should not be treated as an authoritative record. Nothing that you read here constitutes advice medical or otherwise. Always consult with a healthcare professional before making changes to a healthcare plan.
Scott Benner 0:00
Hello, everybody, welcome to Episode 345, the Juicebox Podcast. That didn't feel like enough energy. Let's try it again. Hello, everybody. Welcome to Episode 345 of the Juicebox Podcast. And that was too much. I'm going to shoot right for the middle. Give me a second. Go. Hello, everybody. Welcome to Episode 345 of the Juicebox Podcast on today's show, the CEO of Dexcom Kevin Sayer is here to discuss with me what's been going on with your favorite continuous glucose monitoring company. And there's a lot here short show lots of information. And this is very uncommon, recorded on the day it was dropped. That doesn't usually happen. So this information is up to date, June 15 2020. The Juicebox Podcast is sponsored by the Omni pod. You know what that is, is a tubeless insulin pump. My daughter's actually been wearing it since she was four years old, and she's about to turn 16. The Omni pod tubeless insulin pump is a Marvel and the company who makes it offers an absolutely free, no obligation demo. So they'll send it right to your home, you can try it to see if it's something you're interested in before you move forward. That's of course at my Omni pod.com forward slash juice box, and Dexcom, makers of the G six continuous glucose monitor and the company who does all the stuff you're about to hear about. You can find out more about the dexcom@dexcom.com forward slash juice box. The episode is also sponsored by the Contour Next One blood glucose meter. Of course, everything you need to know about that exists at Contour Next one.com. Just head over there, you can find out all sorts of things about the greatest meter I've ever used, including, if it's possible that you may be eligible for an absolutely free meter. Links to all of these sponsors are available at Juicebox podcast.com. Or right there in the show notes of your podcast player. I am joined today by Kevin Sayer, the CEO of Dexcom. This is Kevin's seventh appearance on the podcast. Kevin took a little time out today from the American Diabetes associations ADF Scientific Sessions. I don't know if you know what that is. But it happens every year. It's this very big event that usually happens in person this year because of COVID-19. Of course, it's happening virtually. And so anyway, Kevin took a little time out to talk to me about what's going on at Dexcom. At some point in this half an hour, we're going to talk about the patient Assistance Program. CGM use in hospitals around COVID-19, the two year anniversary of G six, the G six Pro, which I'm wearing hybrid closed loop partnerships with Omni pod and tandem Medicare, some new things happening in the EU. And the rest. You know, when they did that Gilligan's Island thing they were like in the first couple seasons, they were like there's so many people here we don't know if everybody cares about Marianne yet, so we'll just say and the rest. Trust me, they ended up caring about Marianne, and you're gonna care about everything that Kevin talks about here on the show. I have to do disclaimer very quickly. Nothing you hear on the Juicebox Podcast should be considered advice, medical or otherwise, please always consult a physician before making any changes to your health care plan or becoming bold with insulin. Oh, yeah. How are you finding Ada being online?
Kevin Sayer, Dexcom CEO 3:39
I miss being there. I miss talking to healthcare professionals I've known for a long time I miss going actually to sit tomorrow the scientific sessions and hearing the buzz, it's on the floor. I still think a lot of data is getting presented. And I still think we're learning that we are doing much better with diabetes from done in the past. And in all fairness, Dexcom appears to be in the middle of all this.
Scott Benner 4:02
So that's all good. You really have a head things covered on all fronts. It gets to the point sometimes where I think people get confused and think that companies are one in the same because you know you've got Well, I mean, you've got a relationship with with tandem. And I can't find anybody to say anything bad about control like you that's for certain.
Kevin Sayer, Dexcom CEO 4:23
Great product.
Scott Benner 4:24
Yeah. And what's going on with did on the purchase chain is it's on the pod five is going to be the loop,
Kevin Sayer, Dexcom CEO 4:32
then I don't know their product names. I just know they've restarted they're pivotal and they're get everybody re enrolled and they're pushing to get this thing done. So we can get the horizon system out there. I don't know what they're gonna call it. I just, you know, the presentation, the patients really had a very good experience from a user interface perspective and the time and range data was it was strong comparable to the others. Yeah. So we're looking forward to another integrated system and more For our patients, do you feel
Scott Benner 5:01
like a proud parent, sometimes when you watch these things happen, like recognizing they couldn't happen without XCOM?
Kevin Sayer, Dexcom CEO 5:07
You know, I feel an integral part of it. And I do feel very proud and Oh, my, in all fairness, humbled to be here, because this is so important. Yeah, I would tell you what happens. And the people that work for me tell you the same holiday happens is when these good things happen. I just turned a pressure up to the next one, I am not very good at celebrating. I there's just so much to do.
Scott Benner 5:29
Well, then you're exactly in the right position, I have to say, I look today, because I found myself wondering, and you've been doing this podcast since 2015. This is your seventh or seventh time on. And just looking back to what we were talking about in 2015, and 16, and 17. There's never been a pause. And this will sound like I'm, I'm kissing your butt a little bit. But I'm not. I've been in the space long enough to see that innovation doesn't normally happen this quickly around things with diabetes for people. So it's incredibly exciting.
Kevin Sayer, Dexcom CEO 6:00
No, it is, in fact, we're celebrating our second anniversary of GE six right now. We lost his two years ago, okay. And we're still learning how good it is. We are learning the subtle things we can do to improve it. We are learning how important it is and everybody's lives. And just look forward to to the next wave of innovation. We Oh, yeah. Yeah. And we have moved very quickly. And in a very planned, well executed manner.
Scott Benner 6:30
What are you learning from that two years of data, because you've been on in the past and talked about, like, kind of pie in the sky stuff and always sound like like, you know, we'll be able to see enough data one day that it'll be able to tell you, Hey, don't you think you should Bolus here or something like that? Or is that stuff really, in the works?
Kevin Sayer, Dexcom CEO 6:45
You know why it hasn't happened yet. And it's still conceptually being thought of, I would tell you, if I could look back from when we talked about that two years ago, I'd love to have made more investments on that front. But in all fairness, we made the investments we need to get the technology that affects people right now in their daily lives on the market. Yeah, and and when g six and all fairness, our biggest investment in the past few years is trying to get enough manufacturing scale and get enough product to take care of our patients, right. And we've made some pretty bold promises, we said, we double our capacity by the end of 19. From the start of 19, which we did, we made a promise again, to double capacity by the first of July of this year from the end of last year, which we will achieve that as well. So we'll have the ability to build a lot of G six sensors to take this technology to a lot of places and to a lot more people. So we've kind of been catching up on the physical aspects. And I think now we can turn a bit inward and start looking at this science, this data, these integrations, all these other things and invest a little more time there. On top of going through all the same process. We went through G six, yeah, to get a G seven product out the door to
Scott Benner 7:57
he's not that I'm not in a hurry. g six works great for us. But is there a timeframe for seven?
Kevin Sayer, Dexcom CEO 8:03
We're not where we are we always we're always trying to be quick. But effective. We don't have a launch date for G seven yet. We have disclosed that the trials been delayed because of everything with COVID. Yeah, the centers aren't doing the studies, once we know that study timeframe, and how long it will take us to execute that study then that will give more dates, but like you said, g six has been a great product, it remains a great product. It's well integrated, we'll have more integrations and and we'll continue to improve it and make it better over the next several months anyway, we're not going to abandon all right, right, Mr. g seven come in yet still Well, our patient choose. So we'll continue to to make g six better while we move to to G seven get ready for that, too.
Scott Benner 8:52
So speaking of COVID-19, I guess I wanted to understand a little bit more about the patient Assistance Program. What did you guys put into place when all this happened?
Kevin Sayer, Dexcom CEO 9:02
Yeah, and we've designed a patient Assistance Program, it has not gone live yet it will go live, hopefully, first in July, maybe a little bit before that. We looked at the economy and everything going on. The one thing that was very important to us is to make sure current Dexcom users get taken care of. And Dexcom users may in fact lose their insurance or their jobs during this point in time. And we unfortunately don't have Medicaid coverage in every state and even some of the states where you do have Medicaid coverage, it takes quite a while to qualify. Okay, so we put a program in place for Dexcom patients that literally for $90. Over a six month period patients will get enough sensors and a couple of transmitters to get them through this time. And we will we've had some patients sign up not a lot. I think once we roll it out live, we'll see more that we really wanted to take care of the Dexcom family and doing that.
Scott Benner 9:54
So they're actually able to sign up now getting ready for when it launches. Yes. Cool. I'll put a link to that. In case anybody's and this is going to be for people who lost their insurance, like directly, how do you? How do you figure out who that is?
Kevin Sayer, Dexcom CEO 10:09
What we did is we went to an outside service that has the systems to do all those types of checks and go through and you know, where was your last? I don't know what the process that goes through. We knew we didn't have the systems to do that ourselves. And we did find a company that that is administered types of programs like this for pharmaceutical companies, right? So apply the same type of program to Dexcom. And and go from there.
Scott Benner 10:34
Do you know much about what you guys are learning from the Dexcom being used in hospitals around COVID-19? Rick was on a few weeks ago and was telling me about it. And I don't know if you've learned anything since then.
Kevin Sayer, Dexcom CEO 10:45
You know, we've learned a lot. I haven't listened to Rick's comments, but I can tell you, the first thing we learned is just hospitals operate a little differently than we do. And we've had to learn how to get the product and how to get the cell phones, that it's going to receive the data safe and through the IT systems in the hospital. And we've learned a lot about education. You know, we're used to training patients with diabetes and endocrinologist, we had a new audience. And we had to hear our training towards them. And they understand it, obviously that and we start thinking everybody knows everything about this, and everybody doesn't always know everything about it. We've learned that the the benefits from it are everything we'd hoped they'd be a human action and PP, patients are getting out of the hospital faster if they're putting on insulin drip, that insulin drip is much more well controlled, because you have a CGM data, again, leading to earlier discharge. The biggest benefit quite honestly, for anything in the hospital is when you can improve workflow and make the lives of the people who interact with the patient's better and more effective. And while we're hearing from, you know, from healthcare professionals, we put this on we get them up on Sharon follow, we can monitor them from the hall. And when we get an alert, we're going to deal with it rather than sticking their finger some places every half an hour. Yeah, 40 finger six a day in a hospital bed costs a fortune in nursing and caretaker time. So we've learned that we've learned essential performance the way it does with our regular patients. So we've not seen any abnormalities as far as what these patients are getting as far as compounds interfering with central membranes, which is something we have had many discussions with the FDA about, excuse me. And so
Scott Benner 12:32
that'll all be good. I think we'll gather as much of this data as we can. We made a commitment to the FDA, we'd present it to them. Before we run any further with this, and then talking about what we need to do more to be in a hospital full time. I'm excited for that after Rick came on, I get so many notes from people who are like, Is there gonna be a study, we want to hear about this thing. I was like, it'll happen Hold on a second. So when it happens, I'd love to know about it. Actually, the thing that I kind of got most excited about all the stuff you just said about what's happening is great. But I like the idea of this sort of reverse education is going to happen back to the nursing staff and the doctors so that they can see things about insulin use that I don't believe they thought about in the past. You know, when people are hospitalized, they have a tough time with type one. And I'm excited for what this might do.
Kevin Sayer, Dexcom CEO 13:19
They have a tough time with type twos as well. I remember, many years ago, my mother went to hospital for valve replacement. My mom had type two diabetes, they had a harder time getting her glucose in control than they did, getting her healed up and ready to come home from a heart valve replacement because of the stress that that surgery put on her system. And just the way her body was wired. I think one of the learnings from all this is there's no one size fits all. Yeah. Where people have different physiologies and different ways their bodies and systems react to things and CGM gives you a view? Yeah,
Scott Benner 13:54
I think I really believe that Dexcom in a hospital setting, beyond COVID-19 would be amazing for anybody who uses insulin, because they just don't get they don't always get the care that they need. And actually talking about everybody being different. You guys were very kind and sent me a Dexcom Pro, which I'm about
Unknown Speaker 14:13
a pro I
Scott Benner 14:14
heard How's it going? Well, I'm in my last few hours and I melancholy that it's gonna shut off soon, honestly, because of what I'm, I know that sounds crazy. But as I looked at came up, and it said, 24 hours left in 24 hours felt hopeful. But when it got to six hours, as I call this thing's almost done, you know, and I really felt badly about it, because I'm making slightly different decisions about food based on what I'm seeing. But some of the crazy things that I've seen, I never expected I you know, I'm kind of held up in my home like everybody else. I had to go out and get food the other day. So I jumped in my car, it's hot out, I opened the windows, I'm going to go for a ride by myself. I'm kind of excited I turn on some very loud music, and my blood sugar went up while I was driving to the grocery store and I thought that's just an anomaly, right? But I get out of the car, it goes right back down and settles in. And I come out, get back in the car, turn the music back up and watch my blood sugar go up a little bit. Now not a lot, you know, it's obviously different thing then. But it was a little bit of an adrenaline rush. But there was an adrenaline rush. I was like, wow, I'm excited to go to the grocery store, by the way that felt as sad as it did experience.
Kevin Sayer, Dexcom CEO 15:19
Oh, but the things you learn and the things that people will learn from gee six Pro, particularly like somebody's pre diabetes, or type two diabetes, who hasn't had the type of interaction, you know, type one patients, their bread and butter, and that's the business we're in today. But as we look forward to the future, if you have type two diabetes, what these patients have been told for years is eat less, exercise more and take your meds. But there's nothing that shows them the effect of that. Yeah, when you put g six pro on or G six on and you see the effect of that, you kind of sit back and go, Okay, I can now do something I can now learn.
Scott Benner 16:00
It's really good. It's massive. Because if I told you that I made pizza yesterday from scratch, and that didn't impact my blood sugar as much as a navel orange, I ate the day before. That wouldn't make any sense to somebody like if you if you just said to somebody Look, there's this guy's got type two diabetes, what do you want him to have? This slice of pizza? Or this orange? What do you think's gonna spike his blood sugar less? I don't think anybody would pick the orange over the pizza. But it's really just it's fascinating to watch. And it's fascinating to see how quickly your body. And the reason I asked for it initially was because I talked to so many people about how they use it so and I really wanted to see firsthand how, how it worked like how does the pancreas really work because all I have is what I've kind of gleaned from my daughter all these years, you know, like what should be happening and what gets you back to flat again. And to see that when I eat more sugary foods, my body comes in harder and more aggressive than it does when I eat more complex carbohydrates. That was fascinating to me to see, because I don't get pushed very low. Unless I eat sugar if I have a bunch of sugar, which I don't normally do. But I've been this has been quite a little fun thing for me, I guess I've been experimenting. And so I had a piece of cake with a lot of frosting. And then I was full and would have never done more and did more. And I just washed my blood sugar shoot up and then it pushed it back down to 80. But if I eat pizza, I don't get pushed back down to 80 not nearly that fast. It was it was really fascinating and continues to be
Kevin Sayer, Dexcom CEO 17:30
how the learnings for all of us when you are in this technology are it's really fascinating. The the effect of exercise, effective timing of meals right is dramatic. Yeah. For me, in particular, if I eat that piece of cake you talked about at 10 o'clock at night, that will affect at least till two o'clock the next afternoon for me, no kid, I'll be too high. It takes a long time to my system. And then then I have the big crash like you're talking about. Right work on much lower. And so trying to run on an even keel is quite a challenge. Wow, really sings
Scott Benner 18:06
the cake took me to like 146 and as soon as I got up that high, I got yawn I started yawning I felt tired. Like it was you know, people talk about Oh, it's after lunch. It's it's maybe it's not after lunch, if you don't eat the wrong things, you know, is which is what I took from it. Just so how is this going to get used? Or what's your goal for how it's going to get used in a doctor setting you want them? Well,
Kevin Sayer, Dexcom CEO 18:28
we have you know, we have always had a lot of goals, we still are going to be focused on our intensive insulin world. And we'll design our product and our base technology for that. And it will it will be there and it will be continually offered to those patients over time our next market would be the type two non intensive patient that those patients on other compounds. So they can literally delay if not eliminate the need forever migrating to insulin if they can manage themselves appropriately. And we've learned the effectiveness of some of these drugs. For some of these patients possibly earlier intervention in pre diabetes. I spoke with one physician who's not under chronologist but in a field where there's a lot of diabetes, and she told me she puts all of her patients who have anyone see above a certain level on index comm to see what's going on and then she'll prescribe jardiance or some other type to drug before they hit diabetes to see if she can prevent it from coming.
Unknown Speaker 19:25
Wow. Well if we
Kevin Sayer, Dexcom CEO 19:26
can prevent those costs and keep people healthy like that through CGM use it it's a huge benefit to the system and to people's lives and if you've seen with your G six Pro, it really doesn't bother me much it's it's pretty easy to wear and the data is is very fascinating. Yeah, we would start there I think over time there's fitness uses and health and wellness and giant uses for this. You know a lot of very high powered technology people have warranty six as an experiment and have suggested things to me. Like, every time you eat a meal, you measure the height of the spike and the width is spike and you have a bunch of analytics and graphs that can become literally industry standard type measures for people as they want to give themselves more healthy from a nutrition perspective. I think we can go there, I and then I think over time, what we would like to do with dexcom is then see what other type of analytes and experiences are required for this total health picture. You know, and we probably talked about ketones and lactic acid, as analytes, which is what others have talked about as well. But what other things can we make, it would be important to this world and really become as you look out 10 years, a healthcare sensor company rather than just glucose, right? And then so as we look to the future, though, because we've learned a lot, we've learned a lot, you know, on the electronics and the algorithms and all of these mechanical features that make our system so good, can we apply those technologies to measuring other things, and, and really create a business around around other things. But that being said, there are several hundred million people around the world with diabetes. And we have a market to go after there that is just massive, and they'll continue to do that.
Scott Benner 21:13
Well, I believe him, obviously, both both goals. And after wearing it for 10 days, I just, I been doing intermittent fasting, and I was just at the end of thinking, I don't know if this is something I want to keep doing or not. But after seeing my blood sugar during those intermittent times, I'm like, I'm gonna keep doing this.
Kevin Sayer, Dexcom CEO 21:28
It's no, it is a great thing. Yeah, it absolutely shows that time you spend on eating set you up for a better day.
Scott Benner 21:35
It's crazy. I'm I am fully just amazed with what happens. So with everything, you know, with Ada being right now, what are you guys presenting? What are you sharing with everybody? Is it just everything we're talking about? Or is there more
Kevin Sayer, Dexcom CEO 21:47
no our presentations that we've had some type q presentations, showing that there's benefit there. And some of our partners like on duo presenting really good data, showing you CGM and talk to patients leads to significant agency reductions. We've also presented with our partners tanam control IQ presenting more pediatric data and other day with their system. And the data is extremely compelling that that system is working very well insolate present some horizon data with what they have gone so far. And that data was very compelling, particularly respect to user experience, and how the patients engage with the system. And you know, the time both those systems have tremendous time with the algorithm running, certainly over 95%, which is a big change from systems have been on the market before. So those efforts are advancing. I think, you know, the other thing is continuously the ADA, everything revolves around what the CGM says, There isn't. There are many studies done where CGM is not an outcome anymore. That timing range doesn't become the indicator that everybody's looking for. And what is the timing range of cheap with this drug or this therapy or this? Whatever? I and I think you'll see that move to time and range being more important measure over and over again, to add on day one, see if not being is certainly a more meaningful interpretation of agency than what we have today.
Scott Benner 23:14
Yeah, we had john Welch on recently from from Dexcom. And he was talking about he was really generous, he brought his own data up on the screen while we were recording, and it's pretty awesome. He was I'll tell you, I, when I reached out, I said that I'd like to have somebody on the can really explain standard deviation, that that stuff and and do it at a detailed level because it never gets spoken about. And I have to admit, when I asked, I think everybody was like, you really want to talk about that. I was like, no, it's gonna be great. And people's response to him being on absolutely spectacular because he had it in a way that I mean, you know, he had it in a different better way. And he explained it well. And he went over also how coefficient of variation can be a good telltale for Lowe's. He said, If you keep that number, and I think he said 36% you'll have far fewer lows. I was like, Wow, that's amazing that that kind of information comes from this, you know, and you know, my daughter's life is, is is just on measurably better because of you guys, so I'm just a huge fan, obviously.
Kevin Sayer, Dexcom CEO 24:18
Is that fun talking to somebody like john that's why I love working at Dexcom I can before when we all get back to work someday, right? I can walk down the hall and find somebody like john and say, Okay, tell me something I don't know. And I promise I leave the office with some I don't
Scott Benner 24:36
know every time Oh, I left that conversation very humble and you're
Kevin Sayer, Dexcom CEO 24:40
it's just it's kind of overwhelming sometimes you go well i i guess i do run the place but boy there's a lot to learn No
Scott Benner 24:48
kidding and and your to your other point. I had him for an hour and an hour and 20 minutes into it had I not moved to screen to see something I had to apologize let him go. I had no idea how much time went by. It was Just really, it was riveting. I had such a great time. A couple of things, you're starting to make some advancements in the European Union to what what's happening there.
Kevin Sayer, Dexcom CEO 25:11
We are, you know, Europe is our second biggest market and there are many cat we are in many countries here, we two recent approvals, we think that will be very helpful. One of them is we have a back of the army indication. So it is now labeled to be one in the back of the army, which many patients did off label anyway. But we think that indication is really important for us for a number of fronts, and it ties directly into our second approval. And that's an official designation that we can be used in pregnancy. Our Pregnant Patients have never quit using our product. If they have diabetes, they've been using it. But the back of the arm medication for Pregnant Patients is really important. Because there's one pregnant patient said to me, I've run out of abdomen space, what am I going to do. So having the back of the arm is a is a good thing. There, we are working on both those indications in the US. And we need to figure out what our data plan is there. But ultimately, we'll get that for G six over here. And then the G seven product, we're running a study on the arm, on the abdomen, and for Pete's on the products as well. So we'll have three labeled indications where patients can wear it with that right out of the gate or not gonna
Scott Benner 26:27
wear us again, is that one of the benefits of having the longevity that the company has that you can start looking at those other indications and spending time doing those studies so that you can get more and more on the label.
Kevin Sayer, Dexcom CEO 26:39
Yeah, it is. And it is, as you understand it, and also, as you listen, you know, one of our core values is to listen to patients, and we've heard from numerous patients get us an arm label indication, please. And the pregnancy data that we got from women who've worn this certain pregnancy, the pictures of babies and stuff. We really need an indication for pregnancy where it says hey, and not necessarily a diabetic patient with a gestational diabetic patient, right. I have a twin grandbabies from a daughter law had gestational diabetes, and she's a nurse and was told, keep your blood sugar's under 125. While four finger six a day, you have no idea how many hours you've spent about 125, right? She put a CGM on and man, she knew everything. And when she showed it to her ob gyn, the OB tear, why and says I don't know why Ray doesn't have this. So we need to get to that market for that product.
Scott Benner 27:37
It's important to keep these kids safe. Let me tell you this, and I ask you a question. And then I'll let you go. But I did a series with a person who was pregnant wearing Dexcom. So I talked to her three months in six months in right before she had the baby. And it is it's not for the faint of heart making a baby to begin with. But making one with diabetes is a it's another game altogether. Oh, yeah, we appreciate that. No kidding. Um, Medicare. I didn't ask you about Medicare today.
Kevin Sayer, Dexcom CEO 28:06
Oh, yeah. But I'm happy to talk about Okay, cuz there's a couple things that we've learned. You know, I talked about capacity earlier, and we did not have capacity supply our Medicare patients last year, and we that switch, and we've nearly got almost all of them converted from G five to G six. And so that's been a very good thing. They don't have calibrations. Also, our G six minute care pricing is actually lower for our patients. Because as CMS looked at it, since there are no fingertips required, they dropped what patients would have been paying for finger six before, to Dexcom. So it's the lowest priced offering on the market for Medicare patient right now, on top of that, as you look at our times of uncertainty, where people can't be in the clinic, and where were the highest risk population is probably our senior citizens with diabetes, we offered a tremendous telemedicine opportunity for these patients to be able to have visits with their doctors, and make sure their diabetes is under control. So our Medicare patient population has been extremely served over the past, well served over the past several months. And we look forward to continue to expand there. And we're really happy that we have been able to make this switch have the capacity to do so,
Scott Benner 29:20
you know, I would have to say I'm assuming you don't talk about clarity. Like it's a real diagnostic device. But a lot of people would you do you because I think what I'm seeing is a lot of doctors are like, Look, you can't get in here. But can you tell me on this clarity like what is this? What is this? What is this? It's a it's a great way when you can't move people into a doctor's office especially to take a blood test to help them you know,
Kevin Sayer, Dexcom CEO 29:43
and clarity, you know, and we used to have a three hour delay we dropped that three hours away. It's closer to real time there may be a little bit of time that missed that. But the average be 30 minutes would be all but we dropped that three hour place. Clarity can be used on a much more real Timing decisions for these visits. Yeah,
Scott Benner 30:02
I did it with my daughter, looking right through the same screen that her whole thing and, and it was really amazing. The only thing I didn't go over was that, you know, the company is looking very, very strong financially congratulations. I'm assuming that's probably because the ads on the podcast, you probably don't want to embarrass yourself by thanking me like in while we're being recorded, but
Kevin Sayer, Dexcom CEO 30:22
I love our sources and where we get our patients. I think some of the greatest stories we hear are where people hear about us. And and while Listen, we were running commercials on television now. emails, hey, saw your ad today. And we're we certainly have our direct digital media but I all the places we we run a report to us if somebody's listening to your podcast, I gotta guess our hit rate is pretty high on that patient.
Scott Benner 30:48
Yeah, I well listen to it. If they're listening to what's happening in my house and they're excited for it, then they would at least want to look into it. I would think it's a we're six years now. 5226281 see, oh, sheets, whatever she wants. She's, you know, getting ready to get her driver's license, you know, strong like Healthy Kids. So.
Kevin Sayer, Dexcom CEO 31:07
So when you want when you want advice from me having raised five teenagers, non diabetes related, you can give me a call. I had a daughter. I have been through five teenagers and good luck.
Scott Benner 31:18
Well, I'm just gonna say that. That's quite an accomplishment. Kevin, thanks so much for coming on. I really appreciate
Unknown Speaker 31:23
the time. Of course, we appreciate it. Thank you.
Scott Benner 31:27
Well, Kevin went over so much that I'm going to provide links at Juicebox podcast.com. So there's episode page for this episode, you'll see it go to Juicebox podcast.com. And then everything we talked about, there'll be links to I'll put them in the show notes of the podcast player as well. But just in case you have trouble accessing them there. There'll be right there at Juicebox Podcast comm huge thanks to Kevin for coming on the show and taking some time during this very busy week. While we're thanking people, let me thank you for listening to the Juicebox Podcast and for sharing the show. We had again, a huge month last month and this month is looking to be bigger. So that is because you are sharing and listening. And I appreciate it very much. If you appreciate the show, you can stay on for just a couple more minutes. Because this is how I pay the bills. This episode of the Juicebox Podcast was sponsored by Omni pod, you can get a free no obligation demo of the Omni pod tubeless insulin pump sent directly to your door today by going to my Omni pod.com forward slash juice box. When you do that, and then provide the tiniest amount of information on the pod is going to send a pod right to your home. You can put it on and wear it to see what you think. Is it gonna bother me? Is it bigger than I thought it was? All that stuff? What would it be like to work out with it or take a shower or you know, take a tumble, all that stuff? Those are the kind of things you want to know before you buy. And only pod knows that. I think that's fair. So they're gonna send up demo to your house and let you make the decision. Like I said, I'm wearing the Dexcom Pro right now. And it's one of the things that took me by surprise, I'd never wanted Dexcom before, and I thought I was going to be bothered by it's just existence on me and I have not, I have not even noticed that. It's been terrific. Now Dexcom Pro, that's for physicians, if you're not a physician, this is not what you're interested in. But if you're a physician, check the show notes get in line like Kevin was saying they're gonna start this program very soon. no reason you can't get one for your practice. Everyone else, you're going to want the dexcom g six continuous glucose monitor, go to dexcom.com Ford slash juice box to get started today. So that's simple, high and low alerts. Right. Arden's are set at 70 and 120 we actually get a little beep lets us know if our blood sugars leaving range. And then we just gently guide it back in again. It gets rid of a ton of the highs and lows that come with Type One Diabetes gives you more time back. It also brings a real security knowing not just what your blood sugar is but how fast it's moving and being able to share it with a loved one up to 10 of them actually on an Android or iPhone dexcom.com forward slash juice box and lastly but not leastly the Contour Next One blood glucose meter I've been using hardens all week actually. Because I've been wearing the glucose monitor I've been wanting to match my results. meters terrific. I've used it on Arden for a long time you know when she's sleeping it's you know my job, but I've never used it on myself until just recently. Absolutely everything I say it is and all the other ads goes double now for me Contour Next One small, easy to use, easy to hold. Test trips that you can hit blood miss it once and go back again without ruining it. Nice, bright light for nighttime, fantastic, takes a pretty small blood drop. I didn't have any trouble with it all. Find out about all the sponsors, there's links in the show notes of your podcast player and at Juicebox podcast.com. And don't forget that all the stuff Kevin talked about today that I have links for will be in those exact same places. Little music left. So let me thank you again for your listenership. And for your desire to share the podcast when you're finished with it. I'm seeing really incredible growth over the last couple of months, even when podcasts were affected by the covid 19 crisis, this podcast kept going. So thank you, thank you, thank you. It's a really big deal. And I will continue to do a good job for you best I can appreciate that you share that you listen and that you enjoy.
Seriously, I was really proud while other podcasts stopped putting out content during I guess, April, was a big month for everybody. It's just like, no one's listening to podcasts or we're not putting out and then they slowly kind of put some back. I'm seeing it with a lot of shows. I didn't have to do that. And that was really heartwarming to believe that people cared so much about the show that even when their lives were turned upside down, they still went to it. That really means a lot to me, and I appreciate it. Let me remind you that if you want the pro tip episodes of the podcast, you can go to diabetes pro tip.com. You can of course listen to your podcast app, but for new listeners, or someone who's trying to share just the pro tip episodes, diabetes pro tip.com no es pro tip and juice box docs. It's JU ice bo xdocs.com. I am building a list of listener approved physicians, CDs, that kind of stuff. Check it out if you need one. And if you have one, use that link to send it to me and I'll add your favorite doc. I think that's it right. It's got a big Alright, I'm out. See you guys
